Home » Cancer Research

Category Archives: Cancer Research


Study Finds That Vapes are Just as Bad

According to a study from the University of Rodchester, you can scratch “it is not as harmful to gums and teeth as regular smoke” off the list of reasons to puff on e-cigarettes. In fact, the study shows that they are equally harmful as the old way to take a drag. This study is published with Oncotarget, and its lead is Irfan Rahman Ph.D. who is also professor of Environmental Medicine at the university’s School of Medicine and Dentistry.

Download: http://endnote.com/downloads/style/oncotarget

Given the nature of the study, it really is the first of its kind. Surely, this is due to the fact that e-cigarettes, or “vapes”, as they are commonly known are only gaining popularity in recent years past. This new method of smoking is the latest way for companies to reach a new demographic market within a culture that proves itself to be a rich source of funds year after year.

The method of delivery maybe different with e-cigarettes from traditional methods of smoking, but the results are just the same. The vapors from these devices triggers gum cells to produce inflammatory proteins, which causes stress in turn. This stress often leads to cellular damage and can lead to disease. There is also other intriguing data collected from this study.

According to the results of the study, the flavoring of e-cigarette vapors often makes them more damaging to gums. Add to that, some flavors are even more detrimental than others. Although, there is a need for more studies to say give these findings more weight, it is a good place to start when understanding the effects of nicotine and smoke.

The study is funded by the National institutes of Health and has a slew of collaborators. The publishers, Oncotarget, is a member of Impact Journals. It is a journal that covers anything that has to with oncology. However, Oncotarget is into more than just oncology. The term and organization also covers aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes. The purpose of casting such a wide net is to get rid of borders in medicine where specialties are concerned. Check Oncotarget journal at scimagojr.com

Clay Siegall Is Saving Lives Through Research

Clay Siegall is a man that has accomplished much in his career. His knowledge has been able to do much good when it comes to cancer therapies. Clay Siegall is an individual who received his PhD in genetics from George Washington University and he also received his BS in zoology from the University of Maine Maryland. Clay Siegall is the co-founder of Seattle Genetics and he helped found this company 1999. Seattle Genetics has many different antibiotic based cancer therapies. These are cancer therapies that were able to get accelerated approval by the FDA in 2011.

Dr. Siegall has also spearheaded his company in raising capital, and he has been able to help Seattle Genetics make more than $675 million through private and public financing. Before cofounding Seattle Genetics, Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute for six years, and he also worked with the national Cancer Institute and the National Institute of health.

Newschoolmagazine.com did an article about Siegall, because he was appointed to the Board of Directors for Mirna Therapeutic Science. It was announced that Siegall would be appointed as a member of the Board of Directors in January 2013. Mirna Therapeutics is a therapeutics company that is based in Texas and it was founded in 2007. This is a company that focuses mainly on cancer research therapy, and Dr. Siegall has a huge background in that type of research. Dr. Siegall’s knowledge and experience will help Mirna Therapeutics to continue to advance in developing micro RNA-based therapeutics.

A New Method to Treat Cancer with Seattle Genetics

Clay Siegall is the CEO and the President of Seattle Genetics, a company that specializes in biotechnology with the intention of helping cancerous individuals located all over the world. As the co-founder of Seattle Genetics in 1998, Mr. Siegall has used his science background to not only develop and test, but also research vigorously of new ways to treat cancer without bringing in toxic chemicals into the body. Seattle Genetics was essentially built on scientific innovation among the employees of this company who all have a vision to help others. The leadership of Mr. Clay Siegall has proven to be invaluable for the company as he has not only earned this company the approval of the FDA, but he is also the mastermind behind creating the lead product of antibody-drug conjugates that has heavily tested and experimented on in order to conclude that this drug does in fact help treat the cancerous cells in individual bodies.

The hard work of the workers of this company has resulted in the antibody-drug conjugate which is a drug that has been specifically designed to kill cancer cells within the body. What sets this drug apart from other drugs is the fact that this antibody-drug has been designed to never harm the non-targeted cells within the body. This means that this method of treatment is not only more effective, but it also prevents toxins from entering the body which is a result of other methods such as radiation and chemotherapy. This product has been heavily marketed in over 60 countries around the world in order to offer individuals a cheaper method to cure cancer.

The true mission of this company is to make the world a better place and to reduce the rate of illness. Seattle Genetics is currently in collaboration with Takeda Pharmaceutical Company Limited which has helped with the development with the in-depth clinical program. With a strong feeling of respect and scientific innovation, this company has been able to flourish over the last few years. Clay Siegall hopes to see this company expand into many more countries with the intention of helping people.

Learn more:



Seattle Genetics Continues To Help The Fight Against Cancer

Seattle Genetics was founded in 1997 as a biotechnology company that focuses on developing antibody-based therapies to treat various forms of cancer. In particular, Seattle Genetics focuses on research and development of Antibody-Drug Conjugates, also called ADCs. ADCs are a treatment designed to improve the targeting ability of the immune system’s antibodies to help discover and destroy cancer cells.

Seattle Genetics currently has as its primary drug, ADCETRIS®, or Brentuximab Vedotin, which is currently approved for use as a cancer-fighting drug in over 60 countries. Adcetris is used to treat various CD 30-expressing lymphomas such as Hodgkin lymphoma, cutaneous T-cell lymphoma, and mature T-cell lymphomas. In addition, Seattle Genetics is currently working on additional treatment options, such as Vadastuximab Talirine, which will be utilized to treat Acute Myeloid Leukemia.

Leading Seattle Genetics in the fight against cancer, is its President and CEO Clay Siegall, Ph.D. Dr. Siegall earned his Bachelor of Science in Zoology from the University of Maryland before going on to complete a Ph.D. in Genetics at The George Washington University, in Washington D.C. The University of Maryland named Siegall Alumnus of the Year for Computer, Math and Natural Sciences in 2013 and was honored as the Entrepreneur of the Year by Pacific Northwest Ernst & Young in 2012.

Having served as the President and CEO of Seattle Genetics since 1998. Prior to his work with Seattle Genetics, Clay Siegall worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 through 1997, as well as the National Cancer Institute from 1988 through 1991. Siegall also contributes to the healthcare field by serving on the Board of Directors of three other major pharmaceutical companies. Ultragenyx Pharmaceutical, Mirna Therapeutics, Inc., and Alder Biopharmaceuticals Inc. all greatly benefit from Dr. Siegall’s experience and expertise in the pharmaceutical industry.

Over the last five years, Seattle Genetics has benefited from Siegall‘s leadership and its stock offerings have risen from $17 to over $41 per share.